Literature DB >> 8646405

Acetyl-11-keto-beta-boswellic acid (AKBA): structure requirements for binding and 5-lipoxygenase inhibitory activity.

E R Sailer1, L R Subramanian, B Rall, R F Hoernlein, H P Ammon, H Safayhi.   

Abstract

1. 5-Lipoxygenase (5-LOX) products from endogenous arachidonic acid in ionophore-stimulated peritoneal polymorphonuclear leukocytes (PMNL) and from exogenous substrate (20 microM) in 105,000 g supernatants were measured. 2. The effects of natural pentacyclic triterpenes and their derivatives on 5-LOX activity were compared with the inhibitory action of acetyl-11-keto-beta-boswellic acid (AKBA), which has been previously shown to inhibit the 5-LOX by a selective, enzyme-directed, non-redox and non-competitive mechanism. 3. The 5-LOX inhibitory potency of AKBA was only slightly diminished by deacetylation of the acetoxy group or reduction of the carboxyl function to alcohol in intact cells (IC50 = 1.5 vs. 3 and 4.5 microM, respectively) and in the cell-free system (8 vs. 20 and 45 microM). 4. beta-Boswellic acid (beta-BA), lacking the 11-keto function, inhibited 5-LOX only partially and incompletely, whereas the corresponding alcohol from beta-BA, as well as amyrin, acetyl-11-keto-amyrin, 11-keto-beta-boswellic acid methyl ester had no 5-LOX inhibitory activity up to 50 microM in either system. 5. beta-BA only partially prevented the AKBA-induced 5-LOX inhibition, whereas the non-inhibitory compounds, amyrin and acetyl-11-keto-amyrin, almost totally antagonized the AKBA effect and shifted the concentration-inhibition curve for the incomplete inhibitor beta-BA to the right. In contrast, the non-inhibitory 11-keto-beta-BA methyl ester exerted no antagonizing effect. 6. The results demonstrate that the pentacyclic triterpene ring system is crucial for binding to the highly selective effector site, whereas functional groups (especially the 11-keto function in addition to a hydrophilic group on C4 of ring A) are essential for 5-LOX inhibitory activity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8646405      PMCID: PMC1909340          DOI: 10.1111/j.1476-5381.1996.tb15235.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  10 in total

1.  Protection by boswellic acids against galactosamine/endotoxin-induced hepatitis in mice.

Authors:  H Safayhi; T Mack; H P Ammon
Journal:  Biochem Pharmacol       Date:  1991-05-15       Impact factor: 5.858

Review 2.  5-Lipoxygenase.

Authors:  A W Ford-Hutchinson; M Gresser; R N Young
Journal:  Annu Rev Biochem       Date:  1994       Impact factor: 23.643

3.  Leukotriene antagonists prevent endotoxin lethality.

Authors:  W Hagmann; D Keppler
Journal:  Naturwissenschaften       Date:  1982-12

4.  Boswellic acids: novel, specific, nonredox inhibitors of 5-lipoxygenase.

Authors:  H Safayhi; T Mack; J Sabieraj; M I Anazodo; L R Subramanian; H P Ammon
Journal:  J Pharmacol Exp Ther       Date:  1992-06       Impact factor: 4.030

5.  Inhibition of leukotriene B4 formation in rat peritoneal neutrophils by an ethanolic extract of the gum resin exudate of Boswellia serrata.

Authors:  H P Ammon; T Mack; G B Singh; H Safayhi
Journal:  Planta Med       Date:  1991-06       Impact factor: 3.352

6.  Mechanism of 5-lipoxygenase inhibition by acetyl-11-keto-beta-boswellic acid.

Authors:  H Safayhi; E R Sailer; H P Ammon
Journal:  Mol Pharmacol       Date:  1995-06       Impact factor: 4.436

7.  A novel biologically active seleno-organic compound--V. Inhibition by ebselen (PZ 51) of rat peritoneal neutrophil lipoxygenase.

Authors:  H Safayhi; G Tiegs; A Wendel
Journal:  Biochem Pharmacol       Date:  1985-08-01       Impact factor: 5.858

8.  A novel biologically active seleno-organic compound--VI. Protection by ebselen (PZ 51) against galactosamine/endotoxin-induced hepatitis in mice.

Authors:  A Wendel; G Tiegs
Journal:  Biochem Pharmacol       Date:  1986-07-01       Impact factor: 5.858

Review 9.  Designing therapeutically effective 5-lipoxygenase inhibitors.

Authors:  R M McMillan; E R Walker
Journal:  Trends Pharmacol Sci       Date:  1992-08       Impact factor: 14.819

10.  Production of peptide leukotrienes in endotoxin shock.

Authors:  W Hagmann; C Denzlinger; D Keppler
Journal:  FEBS Lett       Date:  1985-01-28       Impact factor: 4.124

  10 in total
  31 in total

1.  Effect of Boswellia serrata on intestinal motility in rodents: inhibition of diarrhoea without constipation.

Authors:  Francesca Borrelli; Francesco Capasso; Raffaele Capasso; Valeria Ascione; Gabriella Aviello; Rocco Longo; Angelo A Izzo
Journal:  Br J Pharmacol       Date:  2006-04-24       Impact factor: 8.739

2.  Triterpenoid resinous metabolites from the genus Boswellia: pharmacological activities and potential species-identifying properties.

Authors:  Yuxin Zhang; Zhangchi Ning; Cheng Lu; Siyu Zhao; Jianfen Wang; Baoqin Liu; Xuegong Xu; Yuanyan Liu
Journal:  Chem Cent J       Date:  2013-09-12       Impact factor: 4.215

3.  Identification of novel anti-inflammatory agents from Ayurvedic medicine for prevention of chronic diseases: "reverse pharmacology" and "bedside to bench" approach.

Authors:  Bharat B Aggarwal; Sahdeo Prasad; Simone Reuter; Ramaswamy Kannappan; Vivek R Yadev; Byoungduck Park; Ji Hye Kim; Subash C Gupta; Kanokkarn Phromnoi; Chitra Sundaram; Seema Prasad; Madan M Chaturvedi; Bokyung Sung
Journal:  Curr Drug Targets       Date:  2011-10       Impact factor: 3.465

Review 4.  Drug-Herb Interactions in the Elderly Patient with IBD: a Growing Concern.

Authors:  Haider Rahman; Marina Kim; Galen Leung; Jesse A Green; Seymour Katz
Journal:  Curr Treat Options Gastroenterol       Date:  2017-12

5.  Boswellic acid attenuates asthma phenotypes by downregulation of GATA3 via pSTAT6 inhibition in a murine model of asthma.

Authors:  Zhimin Liu; Xiaoyun Liu; Lili Sang; Haifeng Liu; Qinghua Xu; Zhehui Liu
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

6.  Metabolic Profile of 3-Acetyl-11-Keto-β-Boswellic Acid and 11-Keto-β-Boswellic Acid in Human Preparations In Vitro, Species Differences, and Bioactivity Variation.

Authors:  Yonglei Cui; Xiangge Tian; Jing Ning; Chao Wang; Zhenlong Yu; Yan Wang; Xiaokui Huo; Lingling Jin; Sa Deng; Baojing Zhang; Xiaochi Ma
Journal:  AAPS J       Date:  2016-06-21       Impact factor: 4.009

7.  Boswellic acid inhibits growth and metastasis of human colorectal cancer in orthotopic mouse model by downregulating inflammatory, proliferative, invasive and angiogenic biomarkers.

Authors:  Vivek R Yadav; Sahdeo Prasad; Bokyung Sung; Juri G Gelovani; Sushovan Guha; Sunil Krishnan; Bharat B Aggarwal
Journal:  Int J Cancer       Date:  2011-09-12       Impact factor: 7.396

8.  In Vivo Osteoinduction: Evaluating 2-Beta Coxatene as an Immunoinductive Compound and Novel Ingredient for Joint Support.

Authors:  Katherine Spinks; James J Scaffidi
Journal:  Integr Med (Encinitas)       Date:  2016-10

9.  A boswellic acid-containing extract attenuates hepatic granuloma in C57BL/6 mice infected with Schistosoma japonicum.

Authors:  Miao Liu; Peng Chen; Berthold Büchele; Shengjian Dong; Dake Huang; Cuiping Ren; Yuxia Zhang; Xin Hou; Thomas Simmet; Jijia Shen
Journal:  Parasitol Res       Date:  2012-12-28       Impact factor: 2.289

10.  Comparative efficacy and tolerability of 5-Loxin and AflapinAgainst osteoarthritis of the knee: a double blind, randomized, placebo controlled clinical study.

Authors:  Krishanu Sengupta; Alluri V Krishnaraju; Amar A Vishal; Artatrana Mishra; Golakoti Trimurtulu; Kadainti V S Sarma; Smriti K Raychaudhuri; Siba P Raychaudhuri
Journal:  Int J Med Sci       Date:  2010-11-01       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.